Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 18;12(3):e007071. doi: 10.1161/CIRCEP.118.007071

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors.

Circulation: Arrhythmia and Electrophysiology is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Valproic acid (VPA) prevents action potential (AP) prolongation in CREM-IbΔC-X transgenic (TG) mice. A, Representative APs recorded from isolated atrial cardiomyocytes of indicated groups. B, Mean AP amplitude (C) slope and (D–F) action potential duration (APD) until 50, 70, and 90% of repolarization (APD₅₀, APD₇₀, and APD₉₀) in atrial cardiomyocytes after short-term treatment. VPA treatment prevented the APD increase in transgenic myocytes (n=21–35 cardiomyocytes/5–10 isolations; *P<0.05 vs wild-type (WT); †P<0.05 vs vehicle [VEH]). CREM-IbΔC-X indicates CREM (cAMP responsive element modulator) isoform IbΔC-X.